Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia (PROOF)
This study has been terminated.
Sponsored by: FoxHollow Technologies
Information provided by: FoxHollow Technologies
ClinicalTrials.gov Identifier: NCT00504088
  Purpose

To compare the outcome of bypass surgery and plaque excision for treatment of critical limb ischemia in the lower limbs


Condition Intervention Phase
Peripheral Vascular Diseases
Procedure: Bypass
Procedure: Silverhawk Plaque Excision
Phase IV

MedlinePlus related topics: Peripheral Arterial Disease Vascular Diseases
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Single Group Assignment
Official Title: Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia

Further study details as provided by FoxHollow Technologies:

Primary Outcome Measures:
  • Major amputation-free survival

Study Start Date: October 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ischemic rest pain for more than 2 weeks or ulceration or gangrene of the foot or toes (Rutherford Becker Category 4, 5 or 6)
  • Willing and able, as evaluated by the PI, to provide Informed Consent
  • Willing to undergo up to 5 years of clinical follow up visits as scheduled
  • Angiographic pattern of infrainguinal disease that can be reasonably managed either by surgery or plaque excision in the first instance
  • Reconstitution of at least one patent target tibial segment below the knee which provides run-off to the foot
  • The patient must be >18 years of age
  • Target lesion(s) is located at or below the level of the superficial femoral artery
  • Target lesion(s) is >50% stenosed by quantitative vascular angiography
  • Ability to take at least one of the following types of medications: anti- platelet or anti-thrombotic therapy

Exclusion Criteria:

  • Patient has cardiac or cardiovascular comorbidities that would make surgery inappropriate
  • Patient has terminal or Stage 4 cancer
  • Patient has extensive gangrene that requires both a Below-the-Knee amputation and a revascularization procedure
  • Previous stent in the target lesion
  • Active infection at planned incision site
  • The patient is a pregnant woman
  • The patient has significant suprainguinal or Common Femoral disease that can not be treated either prior to or during the index procedure
  • Target Lesion is a Chronic Total Occlusion (CTO) that is greater than 15cm in length and has severe, continuous calcification
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00504088

  Show 31 Study Locations
Sponsors and Collaborators
FoxHollow Technologies
Investigators
Principal Investigator: James F. McKinsey, M.D. Columbia University
  More Information

Study ID Numbers: FHT-P-06-003
Study First Received: July 17, 2007
Last Updated: August 19, 2008
ClinicalTrials.gov Identifier: NCT00504088  
Health Authority: United States: Institutional Review Board

Keywords provided by FoxHollow Technologies:
CLI
Critical Limb Ischemia
PAD
Peripheral Arterial Disease
Artherosclerosis
Leg Pain
Cardiovascular
Artherectomy
Bypass
Peripheral Bypass
PROOF

Study placed in the following topic categories:
Peripheral Vascular Diseases
Vascular Diseases
Pain
Ischemia

Additional relevant MeSH terms:
Pathologic Processes
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009